Fulgent Genetics Inc (FLGT)

Fulgent Genetics, Inc. is a healthcare company focused on clinical diagnostics and therapeutic development. Through its laboratory and testing services, it provides molecular diagnostics, genetic testing, and anatomic pathology services covering areas such as gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology. The company also offers oncology-related tests and sequencer services connected to hereditary cancer, reproductive health, and other diseases. In addition, Fulgent is developing cancer-focused drug candidates through a nanoencapsulation and targeted therapy platform designed to improve the therapeutic profile of new and existing medicines. Its picture genetics platform combines gene probes, data analysis tools, adaptive learning software, and laboratory information systems to help identify health markers in DNA. The company serves physicians, patients, insurers, hospitals, laboratories, government entities, payors, and large corporations. Founded in 2011 and headquartered in El Monte, California, it traded on NASDAQ under the ticker FLGT as common stock.

Jump directly to the stock analysis sections supported by the latest available data.